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Abstract
Background and aims: Among fruits, kiwi is one of the richest in vitamins and polyphenols and has strong anti-oxidant
effects. We aimed to analyze the relationship between the consumption of kiwi and plasma lipid values, fibrinogen, and
insulin resistance in adults within the context of a normal diet and physical-activity.
Methods: Cross-sectional study. Participants (N = 1469), who were free of cardiovascular diseases, completed a visit, which
included the collection of information concerning the participant’s usual diet and kiwi consumption using a previously
validated, semi-quantitative, 137-item food-frequency-questionnaire. Fasting laboratory determinations included plasma
lipids, fibrinogen and insulin resistance. Regular physical-activity was determined using accelerometry.
Results: Consumers of at least 1 kiwi/week presented higher plasma values of HDL-cholesterol (mean difference 4.50
[95 % CI: 2.63 to 6.36]) and lower triglyceride values (mean difference −20.03 [95 % CI: −6.77 to −33.29]), fibrinogen
values (mean difference −13.22 [95 % CI: −2.18 to −24.26]) and HOMAir values (mean difference −0.30 [95 % CI: −0.09
to −0.50]) (p < 0.05, for all comparisons) than those who consumed less than 1 kiwi per week. In an adjusted logistic
regression analysis, this group had a lower odds-ratio for presenting plasmatic fibrinogen concentrations above 400 mg/dL
(OR = 0.68, 95 % CI 0.49 to 0.95), HDL-Cholesterol plasma values below 45 mg/dL (OR = 0.57, 95 % CI 0.36 to 0.91) and a
HOMAir above 3 (OR = 0.61, 95 % CI 0.37 to 1.00).
Conclusions: Consumption of at least one kiwi/week is associated with lower plasma concentrations of fibrinogen and
improved plasma lipid profile in the context of a normal diet and regular exercise.
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Background
A recent systematic review suggests that the advice to
increase fruit and vegetable intake as a single interven-
tion has favorable effects on cardiovascular disease
(CVD) risk factors [1]. Recommendations to increase the
consumption of fruit are based primarily on studies that
indicate that fruit intake may reduce CVD risk through
the beneficial combination of micronutrients, polyphe-
nols and fiber [2–4], many of which have antioxidant
and anti-thrombotic properties [5].
Among fruits, kiwi is one of the richest in vitamins and
polyphenols and has strong anti-oxidant effects [6–8].
Phytochemical constituents of kiwi has health benefits in-
cluding preventive effects against cancer cell growth [9, 10],
oxidative DNA damage [11–13] in addition to cardiovascu-
lar protective properties [2, 14] and anti-inflammatory
properties [12, 15]. The in vitro anti-oxidant effects of kiwi
have been reported [6], and the consumption of kiwi exerts
effects on platelets and plasma lipids, with the potential to
increase the effectiveness of thrombosis prophylaxis [16]
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and improve the treatment of insulin resistance and
diabetes [17].
Increasing evidence from epidemiological studies sug-
gests that elevated plasma fibrinogen concentrations are
associated with an increased risk of cardiovascular disor-
ders, including ischemic heart disease, stroke and other
thromboembolic events [18]. Similarly, high-density
lipoprotein (HDL) cholesterol concentrations are a
strong inverse predictor of cardiovascular events [19]
and elevated blood triglyceride (TG) concentrations and
insulin resistance predict CVD and all-cause mortality in
the general population [20, 21].
Despite all of these findings, we found no studies that
evaluated the association between kiwi consumption and
plasma lipid and fibrinogen values or markers of insulin
resistance in a large and heterogeneous population
within the context of a regular diet and taking into ac-
count factors such as regular physical activity, alcohol
consumption, body mass index (BMI) and the presence
of lipid-lowering drugs.
The aim of this paper is to analyze the relationship be-
tween the consumption of kiwi and plasma lipid values,
fibrinogen, and HOMAir in a large and heterogeneous
sample of adults in the context of a usual diet and regu-
lar physical activity and taking into account the con-
sumption of alcohol and other confounding factors.
Methods
Study design and population
A cross-sectional study was conducted. The findings
presented in this manuscript represent a subanalysis of
the EVIDENT study, whose purpose was to analyze the
relationship between lifestyle and arterial aging in a co-
hort of healthy patients. The principal results were re-
cently published elsewhere [22, 23], and the protocol
(NCT01083082) can be found in a previously published
study [24]. For the sample population, 1553 subjects
aged 20 to 80 years (both sexes) were selected via ran-
dom sampling from the patients of general practitioners
at 6 health centers in Spain distributed throughout the
geography of Spain. The exclusion criteria for the study
included the following factors: known coronary or cere-
brovascular atherosclerotic disease; heart failure; moder-
ate or severe chronic obstructive pulmonary disease;
musculoskeletal disease that limited walking; advanced
respiratory, renal, or hepatic disease; severe mental dis-
ease; treated oncological disease diagnosed in the 5 years
prior to the beginning of the study; terminal illness; and
pregnancy. More details about inclusion/exclusion cri-
teria are showed in the study protocol [24]. The recruit-
ment and data collection period for the study was June
2010 to June 2012. For this purpose, we selected the 1469
individuals for whom kiwi consumption data was col-
lected. A sample-size of 1469 patients was a sufficient
sample for recognizing as statistically significant a differ-
ence in fibrinogen greater than or equal to 15 mg/dL be-
tween the two groups, assuming an alpha risk of 0.05 and
a beta risk of 0.2 in a two-sided test. These groups were
divided according to their consumption of kiwi (i.e.,
greater than or equal to 1 unit/week or less than 1 unit/
week) with a ratio 1:3. According to this calculation, 353
subjects are necessary in the first group and 1059 subjects
are necessary in the second group. The common standard
deviation is assumed to be 87 mg/dL. The study was ap-
proved by the independent ethics committee of the Health
Area of Salamanca, and all participants gave written in-
formed consent for the study, according to the general
recommendations of the Declaration of Helsinki.
Variables and measurement instruments
Laboratory determinations
Venous blood sampling was performed between 08:00 and
09:00 a.m., after the individuals fasted and abstained from
smoking and the consumption of alcohol and caffeinated
beverages for the previous 12 h. The blood samples were
collected in the respective health centers and were analyzed
at the hospital of the city participating in the external qual-
ity assurance programs of the Spanish Society of Clinical
Chemistry and Molecular Pathology. Serum total choles-
terol, HDL-cholesterol and triglyceride concentrations were
measured using standard automated enzymatic methods
[25]. LDL cholesterol was estimated using the Friedewald
equation when the direct parameter was not available.
Fibrinogen concentrations were determined using an
immunoturbidimetric assay [26]. The insulin sensitivity was
determined using the Homeostasis Model Assessment In-
sulin Resistance (HOMAir) [27] in combination with the
following formula: fasting glucose (mmol/l) X fasting
insulin (mU/ml)/22.5.
Assessment of the normal diet and the consumption of kiwi
The regular consumption of kiwi, fruits and total calo-
ries in each participant’s diet was calculated from data
obtained using a previously validated, semi-quantitative,
137-item food frequency questionnaire (FFQ) that was
collected at the time of the interview [28]. The FFQ
included 137 food items, and the participants indicated
the frequencies of consuming the food items using an
incremental scale with nine levels (i.e., never or almost
never, 1–3 times per month, once per week, 2–4 times
per week, 5–6 times per week, once per day, 2–3 times
per day, 4–6 times per day, and more than 6 times per
day). The reported frequencies of food consumption
were converted to the number of daily intakes and
multiplied by the weight of the portion size indicated.
Kiwi consumption and other fruits are expressed in g/
week. For statistical analysis, the sample was divided into
two groups according to the weekly consumption of kiwi
Recio-Rodriguez et al. Nutrition Journal  (2015) 14:97 Page 2 of 9
(i.e., greater than or equal to 1 unit/week or less than 1
unit/week).
Physical activity
Physical activity was estimated using accelerometry. The
subjects wore Actigraph GT3X accelerometers (Actigraph,
Shalimar, FL, USA) that had been validated previously
[29]. The accelerometers were fastened with an elastic
strap to the right side of the waist for 7 consecutive days,
except while bathing and performing activities in the
water. The data were recorded at 1-min intervals. Total
physical activity was expressed in counts/min. The inten-
sity of the physical activity (i.e., low, moderate, or high)
was determined according to the cutoff points proposed
by Freedson et al.[30].
Anthropometric measurements
Body weight was determined on two occasions using a
Seca770 homologated electronic scale (Medical scale and
measurement systems, Birmingham, United Kingdom)
after calibration, with the patient wearing light clothing
and no shoes. These readings were rounded to 100 g.
Height was measured using a Seca 222 portable system
(Medical scale and measurement systems, Birmingham,
United Kingdom), which recorded the average of two
readings; each patient was shoeless in the standing
position. The values were rounded to the closest centi-
meter. Body mass index (BMI) was calculated as weight
(kg) divided by height squared (m2).
Other measurements
A detailed description of the process by which the clinical
data were collected was published previously [24], includ-
ing an assessment of lifestyle habits, such as alcohol con-
sumption and smoking.
According to the American Association of Clinical
Endocrinologists’ guidelines for the management of
dyslipidemia and the prevention of atherosclerosis,
dyslipidemia was defined as the presence of total
cholesterol ≥240 mg/dL or triglycerides ≥200 mg/dl
or the use of lipid-lowering drugs [31].
Statistical analysis
Continuous variables were expressed as the mean ±
standard deviation, and categorical data were expressed
as the frequency distribution. The χ2 test was used to
compare categorical data. The difference in the means
between 2-category of quantitative variables was ana-
lyzed using the independent samples Student’s t-test and
Analysis of variance (ANOVA) for more two categories.
The Bonferroni test was used for comparisons between
subsequent pairs in the case of variables where the
ANOVA showed a statistically significant difference. We
performed two different analyses: an ANCOVA and a
logistic regression model. In both analyses, we consid-
ered the following parameters as dependent variables:
fibrinogen, HDL-Cholesterol, triglycerides and HOMAir;
the consumption of at least 1 kiwi per week was consid-
ered as the independent variable. All models were ad-
justed for potential confounders, and the variables
exhibited statistically significant differences between the
two kiwi consumption categories (i.e., age, gender, total
energy intake-Kcal, total fruit consumption, BMI, alco-
hol consumption and physical activity). Plasma lipids
were also adjusted for the presence of lipid-lowering
drugs. The data were analyzed using the Statistical Pack-
age for the Social Sciences software (SPSS), version 20.0
(SPSS, Chicago, IL, USA). A value of P < 0.05 was
considered statistically significant.
Results
Of the 1469 individuals (892 women, 577 men) included
in this work, 355 (24.2 %) had a mean kiwi consumption
of 1 kiwi or more per week (30.8 % of women and
13.9 % of men).
The mean age of the sample was 54.9 ± 13.8 years,
with no differences in terms of kiwi consumption. With
respect to the dependent variables of this study, the con-
sumers of at least 1 kiwi per week presented higher
plasma values of HDL-cholesterol (mean difference 4.50
[95 % CI: 2.63 to 6.36]) and lower triglyceride values
(mean difference −20.03 [95 % CI: −6.77 to −33.29]), fi-
brinogen values (mean difference −13.22 [95 % CI: −2.18
to −24.26]) and HOMAir values (mean difference −0.30
[95 % CI: −0.09 to −0.50]) (p < 0.05 for all comparisons)
than the subjects who consumed less than 1 kiwi per
week. No differences in total cholesterol, LDL choles-
terol and the percentage of individuals with diabetes or
lipid-lowering treatment were observed (Table 1).
Among the modifiable lifestyle-related parameters, the
consumers of at least 1 kiwi per week have a higher energy
intake (mean difference 153.81 [95 % CI: 53.46, 254.17])
and a higher total fruit consumption (mean difference
211.53 [95 % CI: 183.93, 239.12]) (p < 0.05 both) than
those who consume less than 1 kiwi per week. This group
of individuals has a lower number of smokers (14.1 %), a
lower alcohol intake (27.1 g/week) and lower mean BMI
values (26.4 Kg/m2). In contrast, these individuals undergo
more physical activity (268.3 counts/min) (Table 2).
In the ANCOVA analysis that was adjusted for con-
founders, the consumers of at least 1 kiwi per week had
lower mean values of fibrinogen (363.1 ± 5.4 vs.378.2 ±
2.9 mg/dL, p = 0.018) and triglycerides (105.7 ± 6.5 vs.
125.4 ± 3.5 mg/dL, p = 0.010) than those who consumed
less than 1 kiwi per week. In contrast, the HDL-
cholesterol values of this group are higher than those of
the group that did not consume kiwi (61.0 ± 0.8 vs. 58.6
± 0.4 mg/dL, p = 0.018). The observed differences in
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HOMAir failed to reach statistical significance (1.93 ±
0.05 vs. 1.80 ± 0.09) (Fig. 1).
In the adjusted logistic regression analysis (Table 3), the
consumers of at least 1 kiwi per week had a lower odds ra-
tio for presenting plasmatic fibrinogen concentrations
above 400 mg/dL (OR = 0.68, 95 % CI 0.49 to 0.95), HDL-
Cholesterol plasma values below 45 mg/dL (OR = 0.57,
95 % CI 0.36 to 0.91) and a HOMAir above 3 (OR = 0.61,
95 % CI 0.37 to 1.00) than those who consumed less than
1 kiwi per week. The consumption of at least one kiwi per
week was not significantly associated with the odds of
having high triglyceride plasma concentrations.
Additionally, we have divided the sample into three
groups according to their regular consumption of kiwi
(non consumers, occasional consumers (less than 2 kiwis
per week) or frequent consumers (more or equal than 2
kiwis per week). The frequent consumers have the
highest mean value of HDL-cholesterol and the lowest
mean value of triglycerides, fibrinogen and HOMAir.
After the adjustment for confounders, this trend con-
tinues at the limit of the statistical significance, except
for the HOMAir (Table 4).
Discussion
The consumption of at least one kiwi per week is associ-
ated with lower plasma concentrations of fibrinogen and
triglycerides and higher HDL-cholesterol values in a large
sample of adults. Similarly, the probability of having a
HOMAir below 3 is lower among frequent users of kiwi.
These results support the hypothesis that the particular
characteristics of this fruit mediate anti-inflammatory and
hypolipidemic effects and impact insulin resistance.
Fibrinogen plays a vital role in a number of pathophysio-
logical processes in the body, including inflammation,
Table 1 Clinical characteristics and laboratory determinations of the study population
Less than 1 kiwi/week More or equal than 1 kiwi/week
N = 1114 (75.2 %) N = 355 (24.2 %)
Mean or Number (N) SD or % Mean or Number (N) SD or % p value
Age (years) 54.7 14.0 55.7 12.6 0.203
Gender, male (n, %) 497 44.6 80 22.5 <0.01
Total cholesterol (mg/dL) 213.1 39.8 214.9 35.1 0.414
HDL-Cholesterol (mg/dL) 57.8 15.6 62.3 14.3 <0.01
LDL-Cholesterol (mg/dL) 133.0 36.4 132.7 31.9 0.894
Triglycerides (mg/dL) 125.7 118.9 105.7 75.5 <0.01
Fibrinogen (mg/dL) 376.3 89.9 363.0 82.0 0.019
HOMAir 1.97 1.69 1.67 1.19 <0.01
Diabetes (n, %) 88 7.9 28 7.9 0.992
Lipid-lowering drugs (n, %) 213 19.1 68 19.2 0.988
Table 2 Total energy, fruit consumption and variables related to lifestyles in individuals according to their weekly consumption of kiwi
Less than 1 kiwi/week More or equal than 1 kiwi/week
N = 1114 (75.2 %) N = 355 (24.2 %)
Mean SD Mean SD p value
Total energy (Kcal/day) 2405.5 857.6 2559.3 779.6 0.003
Total fruits (gr/week) 326.8 223.0 538.3 253.8 <0.01
Kiwi (g/week) 32.7 39.3 532.9 365.4 <0.01
Kiwi (g/week/weight) 0.47 0.59 7.90 5.49 <0.01
Vitamin C (mg/day) 191.0 105.6 284.9 113.5 <0.01
Smoking status (n, %)
Smoker 267 24.0 50 14.1 <0.01
Exsmoker 343 30.8 103 29.0
Non smoker 50.3 45.2 202 56.9
Alcohol consumption (gr/week) 48.0 83.5 27.1 51.4 <0.01
BMI (Kg/m2) 27.2 4.6 26.4 4.4 0.005
Physical activity (counts/min) 246.4 137.1 268.3 121.1 0.011
BMI Body mass index
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atherogenesis and thrombogenesis [32]. A novel aspect of
our results is the clear association between the intake of
kiwi and plasma concentrations of fibrinogen. This relation-
ship has not been described previously. Furthermore, this
association is independent of the main determinants of fi-
brinogen concentrations (i.e., age, sex, obesity, an objective
measurement of physical activity regularity, and alcohol
consumption) [32] and remains significant after controlling
for the total amount of calories and fruit per day. In
addition, these results are only observed for kiwi consump-
tion and not for the consumption of other fruits. The
effects of kiwi consumption on platelet aggregation
were studied previously by Duttaroy et al. [16] in a clin-
ical trial that concluded that consuming two or three
kiwi fruit per day for 28 days reduced the platelet
aggregation response to collagen and ADP by 18 %
compared to the controls (P < 0.05). Our results
reinforce this relationship between the consumption of
Fig. 1 Fibrinogen, HDL-cholesterol, triglycerides and HOMAir according to kiwi consumption group. The bar graphs represent the marginal means
and standard deviations adjusted for age; gender; physical activity (counts/min); total energy intake (kcal); total fruit consumption (gr/week), alcohol
consumption (gr/week), body mass index and the presence of lipid-lowering drugs
Table 3 Logistic regression analysis considering fibrinogen, HDL
cholesterol, triglycerides and HOMAir as dependent variables
and consumption of kiwis as the independent variables
Dependent Variable: OR 95 % CI: OR p
Fibrinogena 0.682 0.490 to 0.950 0.024
HDL-Cholesterolb 0.572 0.359 to 0.913 0.019
Triglyceridesb 0.675 0.375 to 1.217 0.192
HOMAirc 0.609 0.371 to 1.001 0.050
Dependent variable: Fibrinogen (<400 mg/dL or ≥ 400 mg/dL); HDL-cholesterol
(<45 mg/dL or ≥ 45 mg/dL); Triglycerides (<200 mg/dL or ≥ 200 mg/dL);
HOMAir (<3 or ≥ 3)
aModel adjusted for age, gender (male = 1; female = 0), Total energy intake
(Kcal/day), Total fruits consumption (gr/week), Alcohol consumption (gr/week),
body mass index and physical activity (counts/min)
bModel adjusted for age, gender (male = 1; female = 0), Total energy intake
(Kcal/day), Total fruits consumption (gr/week), Alcohol consumption (gr/week),
body mass index and physical activity (counts/min) and lipid-lowering drugs
cModel adjusted for age, gender (male = 1; female = 0), Total energy intake
(Kcal/day), Total fruits consumption (gr/week), Alcohol consumption (gr/week),
body mass index and physical activity (counts/min), lipid-lowering drugs and
presence of diabetes
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Non consumption Occasional consumption Frequent consumption
N = 594 (40.4 %) N = 520 (35.4 %) N = 355 (24.2 %) N = 594 (40.4 %) N = 520 (35.4 %) N = 355 (24.2 %)
Mean 95 % CI Mean 95 % CI Mean 95 % CI p value Marginal Mean 95 % CI Marginal Mean 95 % CI Marginal Mean 95 % CI p value
HDL-Cholesterol (mg/dL) ac 57.1 55.8–58.5 58.5 57.2–59.9 62.3 60.8–63.8 <0.001 58.9 57.7–60.1 58.4 57.1–59.6 60.9 59.2–62.5 0.060
Triglycerides (mg/dL)a 129.2 119.5–139.0 121.7 111.3–132.1 105.7 97.8–113.6 0.007 125.2 115.5–134.8 125.0 115.2–134.9 106.5 93.6–119.5 0.050
Fibrinogen (mg/dL) 375.7 367.8–383.6 376.8 369.2–384.5 363.0 354.0–372.0 0.063 377.8 369.9–385.7 378.5 370.5–386.4 363.2 352.5–373.9 0.050
HOMAirab 2.09 1.93–2.25 1.84 1.70–1.98 1.67 1.54–1.81 0.001 1.94 1.81–2.09 1.91 1.77–2.05 1.82 1.63–2.01 0.630
p values are for comparison of sub-groups by ANOVA test with Bonferroni’s post hoc comparisons. aDifference between non consumers and frequent consumers; bDifference between non consumers and occasional
consumers; cDifference between occasional consumers and frequent consumers










kiwi and platelet aggregation but take into account
possible confounding factors that were not previously
analyzed in a representative sample of the general
population; this aspect was not considered in the study
performed by Duttaroy et al. [16]. The proposed mech-
anisms of this effect include the infiltration of the ves-
sel wall by fibrinogen, hemorheological effects caused
by an increase in blood viscosity, increased platelet
aggregation and thrombus formation. Furthermore,
plasma fibrinogen is also a prominent acute-phase
reactant. Elevated concentrations of fibrinogen, which
may occur secondarily to inflammation and are impli-
cated in cardiovascular risk, may operate in part by in-
creasing the reactivity of platelets [33].
Kiwi consumption is related to higher plasma concen-
trations of HDL-cholesterol. This aspect is an important
finding compared to the study of Duttaroy et al. [16]
and reinforces the findings of Gammon et al. [15]. More-
over, this relationship is maintained in models after
adjusting for important confounding factors, such as
regular physical activity and the presence of lipid-
lowering drugs. Further studies [34, 35] have analyzed
the hypolipidemic role of kiwi extract in patients con-
cluding that the consumption of two green kiwis a day
had favourable effects on plasma HDL-Cholesterol. Both
studies suggest that the most likely constituent to exert
the observed effects are polyphenols and other compo-
nents as vitamin C. Also, the green kiwi intervention sig-
nificantly increased apoA1 (the main structural protein
component of HDL) concentrations. The association
with plasma triglyceride concentrations, which was re-
ported by Duttaroy et al. [16] and was also found in our
study, appears to be more uncertain. From a clinical
viewpoint, after adjusting for confounding factors, the
difference in mean plasma triglyceride values between
the two kiwi consumption groups appears to be relevant.
However, the differences in the frequency of consump-
tion between the study performed by Duttaroy et al. and
our study (i.e., 2–3 kiwis per day vs. at least 1 per week,
respectively) may explain the different results obtained
in the two studies. A regular diet typically includes a var-
iety of fruits, including seasonal fruits. This variety in
fruit consumption is the reason why we divided our
study population into two major kiwi consumer groups:
frequent consumers (i.e., at least 1 item per week) and
occasional consumers or non consumers (i.e., less than
once per week). The results of our study indicate an as-
sociation of HDL-cholesterol and triglycerides with kiwi
consumption within the context of a regular diet and in
a large and heterogeneous sample, regardless of the in-
take of other fruits. However, like other studies, no asso-
ciation was observed with total cholesterol and LDL-
cholesterol. This finding is consistent with other studies
where none of the subjects who consumed kiwifruit
exhibited a significant change in the mean of the serum
LDL-Cholesterol compared with the control diet [34, 35].
Gammon et al. concluded that the difference in total fibre
between the kiwi and control interventions may not have
been sufficient to affect LDL-Cholesterol concentrations.
The acute effects of fresh fruit consumption on the
values of insulin resistance has been examined previ-
ously [36]. However, the relationship between kiwi con-
sumption in the context of a regular diet and insulin
resistance, as measured by HOMAir, has not been previ-
ously evaluated. Abe et al. [17] tested in an “in vivo” ex-
periment the effect of a kiwi methanol fraction on
interleukin-6 and monocyte chemoattractant protein-1
mRNA levels. These molecules are proinflammatory adi-
pocytokines that are induced by insulin resistance. The
relationship between kiwi consumption with the insulin
resistance measured by the HOMA index is less clear.
Although there is a tendency after adjustment for con-
founding factors, showing lower HOMA index in those
with frequent consumption of kiwi, this difference did
not reach statistical significance. However, we found a
relationship between insulin resistance and occasional
and frequent consumption of kiwi when we established
a cutoff point of three in the HOMAir. This cutoff was
chosen because it is representative of the general popu-
lation that visits health centers and because in a study of
Spanish non-diabetic population, the diagnostic of insu-
lin resistance was established considering a similar cutoff
point [37].
The main limitation of this study is the cross-sectional
design, which prevents the establishment of causal rela-
tionships between the consumption of kiwi and fibrino-
gen and plasma lipids. Second, the kiwi intake data was
based primarily on a food frequency questionnaire,
which was designed to assess the habitual diet by asking
about the frequency of a limited number of food items.
Finally, we controlled the effect of potential confounders
on the results such as variables related to lifestyles, but
other factors may affect the relationship between kiwi
consumption and fibrinogen and plasma lipids.
Conclusions
In conclusion, a frequent consumption of kiwi in the
regular diet is associated with lower plasma concentra-
tions of fibrinogen, an improved plasma lipid profile. Fur-
ther interventional studies are needed to define the effects
of kiwi consumption on insulin resistance and cardiovas-
cular outcomes.
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